Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 12/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | PPIA | P62937 | 2/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5099974 | 0.86 | PTGER1 (1.00) | PTGER1CYP2C9RXRARXRBRXRG | |
| SCHEMBL5110014 | 0.85 | PTGER1 (0.74) | PTGER1CYP2C9PPIARXRARXRB | |
| SCHEMBL5102961 | 0.83 | PTGER1 (0.57) | PTGER1CYP2C9PPIA | |
| SCHEMBL5102845 | 0.81 | PTGER1 (0.55) | PTGER1PPIAMCL1MRGPRX4 | |
| SCHEMBL5102942 | 0.81 | PTGER1 (0.55) | PTGER1PPIAMCL1MRGPRX4 | |
| SCHEMBL16056330 | 0.80 | MRGPRX4 (0.50) | PTGER1PPIAMRGPRX4 | |
| SCHEMBL5620600 | 0.78 | PTGER1 (0.64) | PTGER1CYP2C9 | |
| SCHEMBL5103134 | 0.78 | PTGER1 (0.61) | PTGER1CYP2C9 | |
| SCHEMBL4886525 | 0.76 | PTGER1 (0.63) | PTGER1CYP2C9PPIAMAPT | |
| SCHEMBL5103311 | 0.76 | PTGER1 (0.59) | PTGER1CYP2C9PPIAMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446222-B2 | Phenyl compounds | GLAXO GROUP LIMITED (GB) | 2008-11-04 | — | — | US | disclosed |
| US-20060235057-A1 | Phenyl compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235057-A1 | Phenyl compounds | RXRB, CYP2C9, RXFP1 | PTGER1 504/4885CYP2C9 2/4885PPIA 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.